Figure 2. Time-to-Event Plots for Complications, Device Revision, and Mortality Out to 6-Month Follow-up in Patients Treated With Leadless VVI vs Transvenous VVI Pacing.

A, Hazard ratio (HR) and cumulative incidence function for 6-month complication based on the Fine-Gray competing risk model. B, HR and cumulative incidence function for 6-month device revision based on the Fine-Gray competing risk model. C, HR and patient mortality rates based on the Cox proportional hazards model. The comparisons of 6-month device revision and patient mortality were not significantly different between groups.